Overview

An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours

Status:
Completed
Trial end date:
2016-02-25
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to examine the safety and potential effectiveness of a drug molecule called 64Cu-SARTATE as a potential new way to detect neuroendocrine cancers.
Phase:
Early Phase 1
Details
Lead Sponsor:
Clarity Pharmaceuticals Ltd